Inhibrx (NASDAQ:INBX) Receives Market Perform Rating from JMP Securities

JMP Securities reaffirmed their market perform rating on shares of Inhibrx (NASDAQ:INBX) in a research note released on Wednesday morning,Benzinga reports.

Inhibrx Stock Down 4.2 %

INBX stock opened at $13.60 on Wednesday. The company has a 50-day simple moving average of $14.68 and a 200 day simple moving average of $14.67. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $18.95.

Insider Transactions at Inhibrx

In other news, Director Jon Faiz Kayyem acquired 69,686 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average price of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the acquisition, the director now directly owns 51,093 shares in the company, valued at $727,053.39. This represents a -374.80 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inhibrx stock. Exchange Traded Concepts LLC acquired a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 9,608 shares of the company’s stock, valued at approximately $148,000. Exchange Traded Concepts LLC owned approximately 0.07% of Inhibrx at the end of the most recent quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.